Dr Georgina Barnett

My current role is based in the College of Life Sciences within the Equality Diversity and Inclusion (EDI) Strategy Team, supporting the College's EDI initiatives, data analysis and progression of the College EDI Action Plan and Athena Swan action plan. I have a broad research background in human disease including cardiovascular disease, oncology and inflammation.

Up to 30% of patients with chronic total occlusion (CTO) of the coronary artery are ineligible for revascularization by conventional angioplasty. Therapeutic enhancement of the collateral circulation may offer a novel solution for the treatment of CTO in these cases.

My most recent scientific research with the late Professor Tony Gershlick (Department of Cardiovascular Sciences, University of Leicester), investigated the use of prolyl hydroxylase inhibitors to target a pro-angiogenic ‘masterswitch’ the transcription factor Hypoxia Inducible Factor-1α (HIF-1α) with the aim of stimulating a local angiogenic signalling cascade to enhance collateral vasculature and antegrade blood flow and thus provide symptom relief for difficult CTO. This work was funded by the NIHR and the British Heart Foundation.

Conference Abstracts
Barnett, GA, Al-Lamee K, Schofield, CJ, Egginton S, Gershlick AH. Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion. Presented at ESC Frontiers in Cardiovascular Biology, 2016.

Barnett GA, Schofield CJ, Al-Lamee K, Casaretto M, Arndt S, Egginton S, Gershlick AH. Angiogenesis as a Therapeutic Option for Untreatable CTO. Heart. 2016; 102:Suppl 4 A2 (Shortlisted (as 1 of 3) for Young Investigators Award, British Cardiovascular Intervention Society, Advanced Cardiovascular Medicine Meeting, January 2016) (Oral presentation).

Barnett G, Kelly D, Flashman E, Schofield C, Gershlick A. Pro- angiogenic effects of Prolyl-Hydroxylase Inhibitor FG-2216 and Potential for Use in a Novel Strategy of Therapeutic Angiogenesis for Difficult Cases of Coronary Total Occlusion. Angiogenesis 2014: 17.1. P-33 DOI 10.1007/s10456-014-9425-6 (Presented at 5th International Meeting on Angiogenesis March 2014, Amsterdam).

Journal Papers
MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002; 21(44): 6809-18.

Murray JC, Barnett G, Tas M, Jakobsen A, Brown J, Powell D, Clelland C. Immunohistochemical analysis of endothelial-monocyte activating polypeptide-2 in vivo. American Journal of Pathology. 2000; 157: 2045-2053.

Barnett G, Jakobsen AM, Tas M, Rice K, Carmichael J, Murray JC. Prostate adenocarcinoma cells release the novel pro-inflammatory polypeptide EMAP-2 in response to stress. Cancer Research. 2000; 60: 2850-2857.

I am a reviewer for Athena Swan, a charter established to support and transform gender equality within higher education (HE) and research.

BSc (Hons) Biology University of Nottingham 1993

MSc in Molecular Pathology & Toxicology University of Leicester 1995

PhD University of Nottingham 1999